• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [23537 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Deucravacitinib (plaque psoriasis) – Benefit assessment according to §35a Social Code Book V]
2023     National Institute for Health and Care Excellence (NICE) Mirikizumab for treating moderately to severely active ulcerative colitis. NICE technology appraisal guidance 925
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report: V21-12B: Comparison of methods: evidence report for the S3 guideline on abortion in the first trimester]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lasmiditan (migraine) – Benefit assessment according to §35a Social Code Book V]
2023     NIHR Health Services and Delivery Research programme Remote monitoring for long-term physical health conditions: an evidence and gap map
2023     National Institute for Health and Care Excellence (NICE) Baricitinib for treating severe alopecia areata. NICE technology appraisal guidance 926
2023     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Effects of treatment and social support measures in comorbidity]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cemiplimab (cervical cancer) – Benefit assessment according to §35a Social Code Book V]
2023     Canary Health Service [Cost-effectiveness of newborn screening for tyrosinemia type I (update)]
2023     Agency for Care Effectiveness (ACE) Presbyopia-correcting intraocular lenses for treating patients with cataract
2023     National Institute for Health and Care Excellence (NICE) Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments. NICE technology appraisal guidance 927
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cemiplimab (NSCLC, combination with platin-based chemotherapy) - Benefit assessment according to §35a Social Code Book V]
2023     Agency for Care Effectiveness (ACE) Minimally invasive glaucoma surgery (MIGS) implants for treating patients with mild to moderate primary open-angle glaucoma (POAG)
2023     National Institute for Health and Care Excellence (NICE) Cabozantinib for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine. NICE technology appraisal guidance 928
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report: V21-12E: Telemedical evaluation: evidence report for the S3 guideline on abortion in the first trimester]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Upadacitinib (Crohn disease) - Benefit assessment according to §35a Social Code Book V]
2023     Agency for Care Effectiveness (ACE) SpaceOAR systems for rectum protection during prostate cancer treatment
2023     National Institute for Health and Care Excellence (NICE) Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction. NICE technology appraisal guidance 929
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Latanoprost/netarsudil (primary open-angle glaucoma and ocular hypertension) – Addendum to Commission A22-129]
2023     WorkSafeBC Causal association between firefighting and hypersensitivity pneumonitis
2023     Agency for Care Effectiveness (ACE) Aortic hybrid stent graft for treating complex aortic disease
2023     National Institute for Health and Care Excellence (NICE) Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments. NICE technology appraisal guidance 930
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Risankizumab (Crohn disease) – Addendum to Commission A22-133]
2023     WorkSafeBC Association between wearing orthosis and developing metatarsal stress fractures
2023     Agency for Care Effectiveness (ACE) Thoracic and abdominal endovascular repair (T/EVAR) for the structural support of aortic aneurysm
2023     National Institute for Health and Care Excellence (NICE) Zanubrutinib for treating chronic lymphocytic leukaemia. NICE technology appraisal guidance 931
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tixagevimab/cilgavimab (COVID-19) - benefit assessment according to § 35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report: V21-12H: Psychological consequences of abortion. Evidence report for the S3 guideline on abortion in the first trimester]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Zanubrutinib (chronic lymphocytic leukaemia) – Addendum to Commission A22-130]
2023     WorkSafeBC Hemorrhoids and heavy lifting
2023     Agency for Care Effectiveness (ACE) Sirolimus-coated percutaneous transluminal coronary angioplasty balloon catheters (SCBs) for patients with coronary artery disease (CAD)
2023     National Institute for Health and Care Excellence (NICE) Decitabine–cedazuridine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (terminated appraisal). NICE technology appraisal guidance 932
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relationship between volume of services and quality of treatment outcome for colorectal cancer surgery]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tixagevimab/cilgavimab (COVID-19) – Benefit assessment according to §35a Social Code Book V]
2023     WorkSafeBC HEPA filters and nanomaterials
2023     National Institute for Health and Care Excellence (NICE) Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies (terminated appraisal). NICE technology appraisal guidance 933
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Trastuzumab deruxtecan (breast cancer, after 1 prior therapy) - Addendum to Commission A22-80]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: evaluation and implementation of digital health solutions - a look at user participation]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Luspatercept (transfusion-dependent beta-thalassaemia) – Benefit assessment according to §35a Social Code Book V]
2023     WorkSafeBC Firefighting and polycythemia vera
2023     National Institute for Health and Care Excellence (NICE) Foslevodopa–foscarbidopa for treating advanced Parkinson's with motor symptoms. NICE technology appraisal guidance 934
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Trastuzumab deruxtecan (breast cancer, HER2+, at least 2 prior therapies) - Addendum to Commission A22-81]
2023     Health Sciences Institute in Aragon (IACS) [Effectiveness, safety and efficiency of subconjunctival drainage devices using an ab-internal approach for primary open-angle glaucoma surgery]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Luspatercept (myelodysplastic syndrome) – Benefit assessment according to §35a Social Code Book V]
2023     WorkSafeBC Efficacy of eye movement desensitization and reprocessing (EMDR) as treatment for major depression
2023     Agency for Care Effectiveness (ACE) Cytosponge for the detection of patients with Barrett oesophagus
2023     National Institute for Health and Care Excellence (NICE) Secukinumab for treating moderate to severe hidradenitis suppurativa. NICE technology appraisal guidance 935
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Loncastuximab tesirine (DLBCL and HGBL) - Benefit assessment according to § 35a Social Code Book V]
2023     WorkSafeBC Low intensity pulsed ultrasound (LIPUS) for preventing fractures
2023     Agency for Care Effectiveness (ACE) Zio XT for ambulatory ECG monitoring for patients suspected to have cardiac arrhythmia
2023     National Institute for Health and Care Excellence (NICE) Idecabtagene vicleucel for treating relapsed and refractory multiple myeloma after 3 or more treatments (terminated appraisal). NICE technology appraisal guidance 936
2023     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Asciminib (chronic myeloid leukaemia, Ph+, after ≥ 2 prior therapies)]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lutetium vipivotide tetraxetan (prostate cancer) – Addendum to Commission A23-01]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Loncastuximab tesirine (DLBCL and HGBL) – Addendum to Commission A23-45]
2023     Agency for Care Effectiveness (ACE) MagTrace and SentiMag for locating sentinel lymph node in patients with breast cancer
2023     Health Technology Wales (HTW) Robot-assisted thoracic surgery
2023     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Brexucabtagene Autoleucel (new therapeutic indication: relapsed or refractory B-cell precursor acute lymphoblastic leukaemia, 26 years of age and above)]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Olaparib (prostate cancer) – Addendum to Commission A23-03]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tisagenlecleucel (diffuse large B-cell lymphoma) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V (expiry of the decision)]
2023     Agency for Care Effectiveness (ACE) Optune for the treatment of newly diagnosed and recurrent glioblastoma
2023     Ontario Health Supplemental Screening as an Adjunct to Mammography for Breast Cancer Screening in People With Dense Breasts
2023     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Valoctocogene roxaparvovec (severe haemophilia A)]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Trastuzumab deruxtecan (breast cancer) – Addendum to Commission A23-07]
2023     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Cost-utility analysis of universal neonatal screening for critical congenital heart disease based on pulsioximetry in Spain]
2023     Agency for Care Effectiveness (ACE) The CADScor System as a rule-out test for symptomatic patients suspected to have coronary artery disease
2023     Center for Drug Evaluation (CDE) [Evaluation of the effectiveness of long-acting antipsychotic injections and future recommendations for mental health care in Taiwan's National Health Insurance System]
2023     Canary Health Service [Software to support decisions for the administration of medicines in neonatal and paediatric intensive care units]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sotorasib (NSCLC) – Addendum to Commission A23-06]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: urinary tract infection in people aged 14 and over - diagnostic guidelines, optimal use of 1st- and 2nd-line treatments and follow-up ]
2023     Agency for Care Effectiveness (ACE) Paige Prostate Detect to assist the diagnosis of prostate cancer
2023     Center for Drug Evaluation (CDE) [Analysis of the effectiveness of various hemophilia treatments in Taiwan]
2023     Canary Health Service [Transcranial direct current stimulation device for the treatment of drug-resistant epilepsy]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Vutrisiran (hereditary transthyretin amyloidosis) - Benefit assessment according to § 35a SGB V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ibrutinib (previously untreated chronic lymphocytic leukaemia) – Addendum to Commission A23-04]
2023     Health Information and Quality Authority (HIQA) Ultra-hypofractionated adjuvant radiotherapy for breast cancer: evidence synthesis to support a generic justification decision
2023     Agency for Care Effectiveness (ACE) HeartFlow FFRCT for the diagnosis of coronary artery disease
2023     Center for Drug Evaluation (CDE) [Review of domestic and international drug addiction replacement treatment policies and cost-effectiveness analysis of methadone treatment in Taiwan]
2023     Canary Health Service [Targeted muscle reinnervation in individuals with amputated limbs]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: barriers and facilitators encountered by women living with a physical disability (PD), intellectual disability (ID) or autism spectrum disorder (ASD) when using perinatal services]
2023     Scottish Health Technologies Group (SHTG) Technology enabled theatre scheduling tools
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Finerenone (CKD stage 1 and 2) – Addendum to Commission A23-14]
2023     Health Information and Quality Authority (HIQA) An overview of national approaches to stockpiling of medical countermeasures for public health emergencies
2023     Agency for Care Effectiveness (ACE) Rapid to aid the diagnosis of patients suspected of stroke
2023     Center for Drug Evaluation (CDE) [Evaluation of the optimal fixed subsidies strategy for pneumococcal vaccination in the elderly]
2023     Canary Health Service [Genicular artery embolization for the treatment of knee osteoarthritis]
2023     Health Technology Wales (HTW) Multi-grip myoelectric upper-limb prosthetics
2023     Health Information and Quality Authority (HIQA) Health technology assessment of the addition of severe combined immunodeficiency (SCID) to the National Newborn Bloodspot Screening Programme
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Finerenone (CKD stage 3 and 4) – Addendum to Commission A23-15]
2023     Health Information and Quality Authority (HIQA) Health technology assessment of the addition of spinal muscular atrophy (SMA) to the National Newborn Bloodspot Screening Programme
2023     Agency for Care Effectiveness (ACE) AcQMap for patients with cardiac arrhythmia
2023     Canary Health Service [Intraoperative radiotherapy in resectable brain tumors and metastases]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: acute exacerbation of chronic obstructive pulmonary disease -diagnostic approach, optimal use of treatments, and follow-up]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dapagliflozin (heart failure with LVEF > 40 %) – Addendum to Commission A23-11]
2023     NIHR Health Technology Assessment programme Implementing early rehabilitation and mobilisation for children in UK paediatric intensive care units: the PERMIT feasibility study
2023     Agency for Care Effectiveness (ACE) KardiaMobile for the detection of atrial fibrillation
2023     Center for Drug Evaluation (CDE) [Assessment of the optimal implementation strategy for pneumococcal vaccination policies in groups at high risk of invasive pneumococcal disease]
2023     Canary Health Service [Clinical effectiveness and cost-effectiveness of the extension of colorectal cancer screening up to 74 years of age in general population]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: Zemaira - congenital alpha1- antitrypsin deficiency]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Belantamab mafodotin (multiple myeloma) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V (expiry of the decision)]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Penile traction therapy for induratio penis plastica]